Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to stop bleeding in rare blood disorder

NCT ID NCT07273721

Recruiting now Disease control Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 12, 2026 · Updated 20 times

Summary

This study tests a new drug called BT200 in 4-6 adults with type 2B von Willebrand disease who have low platelets and a history of bleeding. The drug is designed to slow the breakdown of a key clotting protein, which may raise platelet levels and reduce bleeding. Participants will receive both BT200 and a placebo at different times to compare effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD), TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medical University of Vienna, Department of Clinical Pharmacology

    RECRUITING

    Vienna, State of Vienna, 1090, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.

VON WILLEBRAND DISEASE (VWD), TYPE 2 VON WILLEBRAND DISEASE (VWD), TYPE 2